Needham keeps USD 12.00 target for Inogen stock
Published on 10/17/2026 at 22:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Needham maintained a USD 12.00 target and Buy rating for Inogen on October 1, 2026.
- Second-quarter revenue reached USD 95.08 million in 2026.
- Inogen stock last traded at USD 6.25 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 0.64 percent versus the Nasdaq prior close.
- Inogen will report third-quarter 2026 results on November 5, 2026.
Needham maintained a Buy rating and a USD 12.00 price target for Inogen on October 1, 2026, leaving the target 92.00 percent above the USD 6.25 Nasdaq price. Markets Insider reported that Michael Matson of Needham maintained the rating and target.
Second-quarter revenue and cash
Inogen reported USD 95.08 million of revenue in the second quarter of 2026, up from USD 85.11 million in the first quarter. The company also posted a USD 3.85 million net loss for the quarter, while operating cash flow was positive at USD 2.95 million. Its investor-relations page lists USD 106.8 million in cash, cash equivalents, marketable securities and restricted cash as of June 30, 2026. Inogen identifies the figures as second-quarter results.
Price position and trading activity
Inogen last traded at USD 6.25 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 0.64 percent versus the Nasdaq prior close. The session volume was 193,859 shares against an average volume of 298,426. The 52-week range was USD 5.04 to USD 9.13, placing the stock 24.01 percent above its low and 31.54 percent below its high.
Valuation and next reporting date
The market capitalization was USD 165.9 million on October 16, 2026, and the trailing P/E ratio was minus 6.94. Inogen announced on October 15, 2026 that it will report third-quarter 2026 results on November 5, 2026, after the market closes. Inogen gave the reporting date in its release.
Comparison with peers
Inogen (Nasdaq, USD): minus 0.64 percent, P/E minus 6.94, market capitalization USD 165.9 million
QuidelOrtho (Nasdaq, USD): minus 7.19 percent, P/E minus 0.84, market capitalization USD 885.3 million
iRhythm Technologies (Nasdaq, USD): minus 0.63 percent, P/E minus 252.70, market capitalization USD 3.6 billion
What the next report adds
For Inogen, the November reporting date is the next fixed calendar marker. The current figures combine second-quarter revenue of USD 95.08 million with a USD 3.85 million net loss and a USD 165.9 million market capitalization, keeping operating performance central to the stock's valuation discussion.
Market context: Market report S&P 500.
Inogen stock market data
- Company: Inogen, Inc.
- ISIN: US45780L1044
- Ticker: INGN
- Primary exchange: Nasdaq
- Price Nasdaq (as of October 16, 2026, 4:00 p.m. ET): USD 6.25
- Change versus Nasdaq prior close: minus 0.64 percent
- Market capitalization: USD 165.9 million (as of October 16, 2026)
- 52-week range: USD 5.04-9.13 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
